Advanced and metastatic tumors with complex treatment histories drive cancer mortality.
Here we describe the POG570 cohort, a comprehensive whole-genome, transcriptome and …

Background: Many medications pose greater health risks when prescribed for older adults,
compared with available pharmacologic and nonpharmacologic alternatives. We sought to …

Objectives: to measure sex differences in the risk of receiving potentially inappropriate
prescription drugs and to examine what are the factors that contribute to these differences. Design…

Oncology biological products are some of the most expensive drugs on the market and are
a growing financial burden on patients and health-care systems. By 2020, numerous major …

Background Limited data exist on the real‐world costs of applying whole‐genome analysis (
WGA ) in a clinical setting. We estimated the costs of applying WGA to guide treatments for …

Background Next-generation sequencing (NGS) technologies have seen variable adoption
in the clinic. This is partly due to a lack of clinical and economic studies, with the latter …

Genomic testing is becoming routine for diagnosing rare childhood genetic disease. Evidence
underlying sustainable implementation is limited, focusing on short-term endpoints such …

Health technology assessment (HTA) can be used to make healthcare systems more
equitable and efficient. Advances in precision oncology are challenging conventional thinking …

This paper reports on end users' perspectives on the use of a blockchain solution for private
and secure individual “omics” health data management and sharing. This solution is one …

Objectives: We quantify patterns in prescription opioid dispensations to individuals who
suffered a prescription opioid-related death. In addition, we examine the relationship between …